We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Arca have introduced new tools for property risk management and created a marketplace to trade portfolio risks to match buyers and sellers of financial products connected to the performance of real estate. They are opening up the concept of short term property market risk management for property portfolio managers.  
days to go: Expired investment: £575,000
The world's first automated suturing tools for safe closure of standard and endoscopic wounds. Sutrue have already patented their devices and use industry-standard needles to offer clinical quality with improved speed and accuracy at the touch of a button. Needles are held in disposable cartridges as a safety feature to prevent injury when piercing skin with contaminated needles. This protects staff both during and after surgery for those working in medical and veterinary environments. Sutrue is raising finance for the production process of their equipment, as well as applying for CE regulation via medical evaluations to receive approval to deploy their products in human and animal surgeries.
days to go: Expired investment: Withheld
Projekt Rising (PR) is an automated project management Software as a Service (SaaS) portal that delivers projects to clients by replacing freelance teams and project managers with intelligent automation. The platform provides services such as video production, web and print content, and e-learning projects. It asserts that its model in the interactive and pharmaceutical industries has led to delivery times being cut in half, costs reduced by >50%, with the highest industry quality standards being maintained throughout. PR aims to be a contender in the £57 billion Project Management Professional (PMP) market. It will use the investment to grow its business across different verticals.
days to go: Expired investment: £51,060
ITIG have developed software to aid in understanding the investment process, as well as reducing the associated costs of investing. Using their licensed methodologies, retail and institutional investors will see return funds which are more predictable when investing in Exchange Traded Funds (ETFs), resulting in highly diverse and low-cost investment portfolio.
days to go: Expired investment: £67,000
Vmoto’s primary business is B2B leasing of electric delivery scooters for local delivery of food and goods.  Its mission is to displace the use of petrol scooters in the fast-growing local delivery industry, deploying electric scooters which are cheaper to run than the incumbent petrol scooters owing to the use of electricity, which is 1/10th the cost per mile of petrol. 
days to go: Expired investment: £100,000
Over the past 8 years, Advatech Healthcare has created Hippo, a proven disabled and non-emergency patients transportation services (NEPTS) in the Essex area. Due to its dependability and efficiency, Hippo is now poised to become the UK's best national wheelchair accessible healthcare services on a wearable technology platform. According to the Office for Technology Statistics data, there are 13.37 million people disabled in the UK who lack dedicated non-emergency transportation. Hippo could save the National Health Service (NHS) up to 60% on transportation costs increasing faster hospital bed rotation and providing dedicated transportation for disabled and non-emergency patients with a medically trained staff. It also offers medical and technological necessities not offered by many leading operators. Currently, the company operates within the Essex area. By the end of 2020, the company aims to commence seven new contracts it has signed with the NHS. It also signed a deal with Cambridge Adult Social Care that is expected to close, within a 5-year term and generate over £200,000 per year.

Pitch Rated

81%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
AgPlus has created a diagnostic platform for detecting human diseases and delivering laboratory instrument results instantly, whilst keeping in mind the business requirements and unmet requirements. The company works in collaboration with leading diagnostics companies to improve and share products quickly and globally. It aims is to become known as a leader in Point of Care diagnosis.
days to go: Expired investment: £65,004
Trustco Capital is a value-added financial intermediary that acts as a bridge between suppliers and users of capital. Through its investor network, the company supports entrepreneurs and startup enterprises with capital allowing their business to advance further. The company's partnership venture, ‘The Envestry Investment Management Programme’, allows Trustco, as a licensee, the ability to introduce its investor client network and its deals to Envestors and the other licensees leading to a combined investor network of over 6,000+ individuals. This also allows users to view 20 to 30 deals that are mostly SEIS and EIS eligible backed by the Financial Conduct Authority (FCA). 

Pitch Rated

38%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
Butterwire is a professional research and portfolio analyst platform designed for high conviction low turnover active equity managers. Butterwire's AI web application was launched in June 2018 and is used by all active equity investors aiming to generate higher returns, with faster stock selection, longer investment horizons, lower portfolio risk, and less trading. The application assists active investors with their top 3 challenges: find opportunities, minimise risk, and keep aware. It is built by and for professionals but is accessible to individual investors, too. The company will utilize 10% of the proceeds to operations, 25% to development, 15% to research, 40% to business development, and 10% to administration.
days to go: Expired investment: Withheld
Antev Limited (Antev) is a clinical-stage biopharmaceutical firm which focuses on the evolution of a drug used for prostate cancer, Teverelix TFA. The company is working on growing its copyright protection and is currently developing phase IIb clinical plans for prostate cancer. Antev is a pre-revenue company that aims at increasing its shareholder value by progressing the development of teverelix TFA towards registration whose approval is anticipated from 2023 onwards. The proceeds will be used for production, IP development, working capital and to develop a phase IIb repeat dosing clinical trial in prostate cancer.
days to go: Expired investment: Withheld
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph